Biolase Inc.

0.7530-0.0313-3.99%Vol 3.21M1Y Perf 48.69%
Jun 15th, 2021 16:00 DELAYED
BID0.7501 ASK0.7575
Open0.7869 Previous Close0.7843
Pre-Market- After-Market0.74
 - -  -0.01 -1.33%
Target Price
2.00 
Analyst Rating
Strong Buy 1.50
Potential %
165.60 
Finscreener Ranking
★★+     48.03
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★+     43.29
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★+     39.78
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap113.25M 
Earnings Rating
Buy
Price Range Ratio 52W %
40.16 
Earnings Date
13th May 2021

Today's Price Range

0.73250.7870

52W Range

0.24501.51

5 Year PE Ratio Range

-2.10-1.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
4.21%
1 Month
7.71%
3 Months
-20.29%
6 Months
167.50%
1 Year
48.69%
3 Years
-39.76%
5 Years
-87.34%
10 Years
-97.31%

TickerPriceChg.Chg.%
BIOL0.7530-0.0313-3.99
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Financial StrengthValueIndustryS&P 500US Markets
3.90
5.10
0.35
0.55
-6.50
Leverage Ratio 3.00
ProfitabilityValueIndustryS&P 500US Markets
29.00
-58.10
-56.50
-46.30
-68.14
RevenueValueIndustryS&P 500US Markets
26.11M
0.17
-19.55
-13.14
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.05-0.06-20.00
Q04 2020-0.04-0.07-75.00
Q03 2020-0.06-0.21-250.00
Q02 2020-0.19-0.1236.84
Q01 2020-0.18-0.19-5.56
Q04 2019-0.06-0.13-116.67
Q03 2019-0.25-0.250.00
Q02 2019-0.20-0.1525.00
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.210.00-
6/2021 QR-0.0469.23Positive
12/2021 FY-0.14--
12/2022 FY-0.08--
Next Report Date-
Estimated EPS Next Report-0.05
Estimates Count1
EPS Growth Next 5 Years %15.00
Volume Overview
Volume3.21M
Shares Outstanding150.40M
Trades Count5.89K
Dollar Volume11.29M
Avg. Volume19.37M
Avg. Weekly Volume5.76M
Avg. Monthly Volume3.70M
Avg. Quarterly Volume5.51M

Biolase Inc. (NASDAQ: BIOL) stock closed at 0.753 per share at the end of the most recent trading day (a -3.99% change compared to the prior day closing price) with a volume of 3.24M shares and market capitalization of 113.25M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 157 people. Biolase Inc. CEO is John R. Beaver.

The one-year performance of Biolase Inc. stock is 48.69%, while year-to-date (YTD) performance is 80.71%. BIOL stock has a five-year performance of -87.34%. Its 52-week range is between 0.245 and 1.51, which gives BIOL stock a 52-week price range ratio of 40.16%

Biolase Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 3.75, a price-to-sale (PS) ratio of 4.52, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -79.56%, a ROC of -87.06% and a ROE of -251.70%. The company’s profit margin is -68.14%, its EBITDA margin is -56.50%, and its revenue ttm is $26.11 Million , which makes it $0.17 revenue per share.

Of the last four earnings reports from Biolase Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Biolase Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Biolase Inc. is Strong Buy (1.5), with a target price of $2, which is +165.60% compared to the current price. The earnings rating for Biolase Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biolase Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biolase Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 35.01, ATR14 : 0.06, CCI20 : 79.45, Chaikin Money Flow : 0.00, MACD : 0.01, Money Flow Index : 72.46, ROC : 7.01, RSI : 51.47, STOCH (14,3) : 48.79, STOCH RSI : 0.23, UO : 48.92, Williams %R : -51.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biolase Inc. in the last 12-months were: John R. Beaver (Buy at a value of $30 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.50

Biolase Inc.

Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

CEO: John R. Beaver

Telephone: +1 949 361-1200

Address: 4 Cromwell, Irvine 92618, CA, US

Number of employees: 157

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

90%10%

Bearish Bullish

53%47%

Bearish Bullish

64%36%

News

Stocktwits